415 related articles for article (PubMed ID: 28373470)
1. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
3. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
[TBL] [Abstract][Full Text] [Related]
4. Detection of preoperative serum anti-p53 antibodies in gastric cancer.
Nakajima K; Suzuki T; Shimada H; Hayashi H; Takeda A; Ochiai T
Tumour Biol; 1999; 20(3):147-52. PubMed ID: 10213922
[TBL] [Abstract][Full Text] [Related]
5. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
6. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
Yamaguchi T; Takii Y; Maruyama S
Surg Today; 2014 Aug; 44(8):1529-35. PubMed ID: 23975589
[TBL] [Abstract][Full Text] [Related]
9. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
10. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
11. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
12. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
[TBL] [Abstract][Full Text] [Related]
13. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
[TBL] [Abstract][Full Text] [Related]
14. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
[TBL] [Abstract][Full Text] [Related]
15. Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.
Takahashi R; Sakamoto K; Sugimoto K; Motegi S; Tsukamoto R; Ichikawa R; Okazawa Y; Aoki J; Ishiyama S; Takahashi M; Kojima Y; Okuzawa A; Tomiki Y; Matsuoka J
Dis Markers; 2019; 2019():2721876. PubMed ID: 31929839
[TBL] [Abstract][Full Text] [Related]
16. Unusually high levels of serum p53 antibody in recurrent gastric cancer.
Kunizaki M; Hamasaki K; Wakata K; Hidaka S; Nagayasu T; Kinoshita Y
Clin J Gastroenterol; 2017 Dec; 10(6):503-507. PubMed ID: 28952039
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
[TBL] [Abstract][Full Text] [Related]
18. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.
Okada R; Shimada H; Otsuka Y; Tsuchiya M; Ishii J; Katagiri T; Maeda T; Kubota Y; Nemoto T; Kaneko H
Surg Today; 2017 Dec; 47(12):1492-1499. PubMed ID: 28508195
[TBL] [Abstract][Full Text] [Related]
20. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
